Clinical Trial

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

Study acronym: THARROS
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
Protocol Amendment History 3 changes
notable Trial sites expanded: 917 -> 920 locations 2026-05-14
notable Primary completion moved earlier: 2028-03-07 -> 2027-12-03 2026-05-14
minor Completion moved earlier: 2028-03-07 -> 2027-12-03 2026-05-14
Trial Details
NCT Number NCT06283966
Lead Sponsor AstraZeneca
Conditions COPD (Chronic Obstructive Pulmonary Disease)
Enrollment 5,250 participants
Start Date 2024-02-21
Primary Completion 2027-12-03 (estimated)
Study Completion 2027-12-03 (estimated)
Updated on ClinicalTrials.gov 2026-06-24